Bayer's Legal and Financial Crucible: A Fortnight of Reckoning

Bayer's share price rally hinges on a US Supreme Court hearing on April 27, 2026, which could eliminate billions in Roundup liabilities, while a $7.25B settlement advances and pharma growth offsets legal risks.

Bayer shares, having nearly doubled over the past twelve months to trade around €40.60, are bracing for a defining fortnight. The company faces a convergence of critical events that will test the durability of its recent rally, with a landmark US Supreme Court hearing poised to fundamentally reshape its multi-billion euro legal liabilities.

The focal point is the oral argument scheduled for April 27, 2026, before the highest US court. Bayer’s appeal centers on the legal doctrine of preemption, arguing that the federal FIFRA statute overrides state-level warning requirements for its glyphosate-based herbicide Roundup. A favorable ruling would invalidate the legal basis for tens of thousands of pending Non-Hodgkin Lymphoma lawsuits nationwide. The US Solicitor General’s office has backed Bayer’s position, and the Environmental Protection Agency’s longstanding stance that glyphosate is not carcinogenic supports the federal argument. However, attorneys general from 18 states, including Texas and Florida, have filed briefs defending state sovereignty, highlighting the legal split that prompted the Supreme Court to take the case.

Financially, the stakes are colossal. The conglomerate has provisions of €11.8 billion for litigation, predominantly for Roundup. For 2026 alone, the company anticipates related cash outflows of approximately five billion euros, an amount significant enough to push its annual free cash flow deep into negative territory. A positive Supreme Court decision would sever this persistent financial drain, a shadow that has lingered since the Monsanto acquisition in 2018.

Simultaneously, Bayer is advancing a $7.25 billion settlement package, which received preliminary court approval in Missouri. Claimants have until June 4 to opt out of this agreement, which acts as a parallel risk-management strategy. Since 2018, the company has already spent over $11 billion to resolve litigation.

Operational performance provides a counterweight to these legal uncertainties. The pharmaceutical division is delivering robust growth, allowing management to reaffirm its full-year guidance despite US import tariffs. Bayer expects 2026 sales of 45 to 47 billion euros and an adjusted EBITDA of 9.6 to 10.1 billion euros. A trade agreement caps tariffs on most European goods at 15%, a buffer the company states is already factored into its plans.

Key to this resilience is the drug Kerendia, which posted currency-adjusted sales growth of 88% in 2025. A recent EU approval for heart failure treatment opens access to additional patient groups, with management targeting peak sales exceeding three billion euros for this product alone. Other growth drivers include Nubeqa, Lynkuet, and Asundexian. Supporting this momentum, Nelson Ambrogio is set to take over leadership of the US pharmaceuticals business on May 1.

The sequence of pivotal events begins with the virtual Annual General Meeting on April 24. Shareholders will vote on a maintained dividend of €0.11 per share and the election of two new supervisory board members, Marcel Smits and Alfred Stern. The company has also made progress on its balance sheet, reducing net financial debt by 8.5% to approximately €29.8 billion.

The final Supreme Court verdict is expected in the latter half of June. A ruling in Bayer’s favor would remove a monumental overhang, potentially validating the stock’s significant recovery. With the share price holding nearly 20% above its 200-day moving average, the coming weeks will determine whether the structural uptrend remains intact or confronts a renewed wave of financial and legal pressure.